Abstract：Objective To investigate the relationship between serum liver enzyme level and atrial fibrillation (AF) in patients with coronary heart disease(CHD). Methods A total of 1520 patients diagnosed with CHD from January 2018 to January 2020 were collected from the Department of Cardiovascular Medicine, Changzhou Wujin People’s Hospital, Jiangsu Province. The baseline data, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ glutamyl transpeptidase (GGT), personal history, and past history of AF and non-AF patients at admission were compared. Multi-factor logistic regression analysis was carried out to explore the independent risk factors for AF in CHD patients, and the receiver operating characteristic (ROC) curve was drawn. Results There were 152 patients with AF on admission, and the incidence of AF was 10%. The comparison of the clinical data of AF and non-AF patients showed that, in GGT, age, history of hypertension, and history of acute coronary syndrome (ACS), the differences were highly significant (P ＜ 0.01); there were statistical significances in AST and ALT (P ＜ 0.05). Multiple logistic regression analysis showed that, GGT [OR = 1.018, 95%CI (1.013-1.024)], age [OR = 1.030, 95%CI (1.012-1.048)], history of hypertension [OR = 2.667, 95%CI (1.671-4.257)], and ACS history [OR = 2.960, 95%CI (1.896-4.622)] were independent risk factors for AF (P ＜ 0.01). ROC curve was drawn and it was found that the area under the curve of GGT was 0.693 in predicting the occurrence of AF. Conclusion In CHD patients, liver enzyme level is associated with the occurrence of AF, especially the elevation of GGT is independently associated with the presence of AF, and GGT may be a circulating marker of AF risk.
[1] Lippi G，Sanchis-Gomar F，Cervellin G. Global epidemiology of atrial fibrillation：An increasing epidemic and public health challenge [J]. Int J Stroke，2021，16（2）：217-221.
[2] Li Y，Wu YF，Chen KP，et al. Prevalence of atrial fibrillation in China and its risk factors [J]. Biomed Environ Sci，2013，26（9）：709-716.
[3] Kim YG，Han KD，Choi JI，et al. Non-genetic risk factors for atrial fibrillation are equally important in both young and old age：A nationwide population-based study [J]. Eur J Prev Cardiol，2021，28（6）：666-676.
[4] 李春兰，裴丽娟，侯鹏.心房颤动相关的生物学标记物[J].中国心血管杂志，2020，25（4）：397-400.
[5] Ruttmann E，Brant LJ，Concin H，et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality：an epidemiological investigation in a cohort of 163，944 Austrian adults [J]. Circulation，2005，112（14）：2130-2137.
[6] Markus MR，Meffert PJ，Baumeister SE，et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population：The Study of Health in Pomerania （SHIP） [J]. Atherosclerosis，2016， 245：123-131.
[7] Lee SR，Choi EK，Han KD，et al. Association between γ-glutamyltransferase level and incidence of atrial fibrillation：A nationwide population-based study [J]. Int J Cardiol，2017，245：149-155.
[8] 马长生，郭雪原.冠心病合并心房颤动的抗栓治疗策略[J].中华心血管病杂志，2014，42（5）：372-373.
[9] Zoni-Berisso M，Lercari F，Carazza T，et al. Epidemiology of atrial fibrillation：European perspective [J]. Clin Epidemiol，2014，6：213-220.
[10] Lin CS，Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation [J]. Cell Mol Life Sci，2008，65（10）：1489-1508.
[11] Sinner MF，Wang N，Fox CS，et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation [J]. Am J Cardiol，2013，111（2）：219-224.
[12] Alonso A，Misialek JR，Amiin MA，et al. Circulating levels of liver enzymes and incidence of atrial fibrillation：the Atherosclerosis Risk in Communities cohort [J]. Heart，2014，100（19）：1511-1516.
[13] Liu CF，Zhou WN，Guo TM，et al. Liver Enzymes and the Risk of Atrial Fibrillation：A Meta-Analysis of Prospective Cohort Studies [J]. Genet Test Mol Biomarkers，2019， 23（12）：865-870.
[14] Whitfield JB. Gamma glutamyl transferase [J]. Crit Rev Clin Lab Sci，2001，38（4）：263-355.
[15] Auer J. What does the liver tell us about the failing heart? [J]. Eur Heart J，2013，34（10）：711-714.
[16] 乔杰，宋艳红.谷氨酰转肽酶的研究进展[J].医学理论与实践，2019，32（5）：651-653.
[17] 方填源，陈哲林，劳彩光，等.冠心病患者血浆miR-10a、miR-342-5p表达与炎性因子的关系及其预测价值[J].疑难病杂志，2021，20（1）：31-36.
[18] 刘春燕，刘小燕，李平，等.冠心病患者PCSK9基因V312F位点多态性与斑块性质，脂代谢及细胞因子的相关性[J].疑难病杂志，2020，19（1）：4-7.
[19] 陈智阳.冠心病患者介入治疗前后的血小板功能,血流变学指标检测及其临床意义[J].中国医药科学，2021， 11（5）：226-229.
[20] Fraser A，Harris R，Sattar N，et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake：analysis of the British Women’s Heart and Health Study and Meta-Analysis [J]. Arterioscler Thromb Vasc Biol，2007，27（12）：2729-2735.
[21] Wannamethee SG，Lennon L，Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes [J]. Atherosclerosis，2008，201（1）：168-175.
[22] Kirchhof P，Benussi S，Kotecha D，et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Eur J Cardiothorac Surg，2016，50（5）：e1-e88.
[23] Cho EJ，Han K，Lee SP，et al. Liver enzyme variability and risk of heart disease and mortality：A nationwide population-based study [J]. Liver Int，2020，40（6）：1292-1302.
[24] Yang W，Kang DW，Lee SH. Effects of Gamma-Glutamyl Transferase on Stroke Occurrence Mediated by Atrial Fibrillation [J]. J Clin Neurol，2020，16（1）：60-65.
[25] Masson S，Aleksova A，Favero C，et al. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation：data from the GISSI atrial fibrillation trial [J]. Heart，2010，96（23）：1909-1914.
[26] Jiang S，Jiang D，Tao Y. Role of gamma-glutamyltransferase in cardiovascular diseases [J]. Exp Clin Cardiol，2013，18（1）：53-56.
[27] Coku V，Shkembi X. Serum Gamma-glutamyltransferase and Obesity：is there a Link? [J]. Med Arch，2018，72（2）：112-115.
[28] Bui AL，Horwich TB，Fonarow GC. Epidemiology and risk profile of heart failure [J]. Nat Rev Cardiol，2011，8（1）：30-41.
京公网安备 11010502046598号